Skip to content
EMT6 Mouse Model
Each year, within the United States, advanced aggressive variations of breast cancer contribute to a significant number of new cases and fatalities. Immuno-oncology research greatly benefits from the EMT6 tumor model, a triple-negative mammary carcinoma tumor, due to its relevance and reliability in studying cancer and metastatic diseases.
EMT6 Syngeneic Breast Cancer Model
We have characterized the EMT6 mouse mammary carcinoma in a syngeneic flank model in Balb/c mice for study of primary tumors and late-stage metastatic disease.
Metastatic Potential
Our EMT6 tumor model uses BALB/c mice, and reflects the tumorigenicity of metastatic mammary cancers, providing a valuable platform for drug discovery.
Immune Response and Treatments
The EMT6 tumor model is immunocompetent, therefore it can be employed in the study of drugs and their impact on the immune system, and to evaluate immunomodulatory therapies.
Fast and Reproducible
EMT6 is distinguished by high immunogenicity and rapid tumor kinetics, providing dynamic tumor environments to aid in your studies.
EMT6 Mouse Mammary Carcinoma
EMT6 is a triple-negative mammary carcinoma with a less aggressive metastatic potential though it adopts pulmonary metastasis readily upon implantation.
Commonly Requested Endpoints
Histopathology
Our customizable histopathological analysis can help evaluate tumor microenvironments, track tumor progression and metastases and inform treatment decisions.
Flow Cytometry
Our flow cytometry expertise can help characterize tumor-infiltration T lymphocytes, identity immune biomarkers, and so much more.